BREAKTHROUGH BREAST CANCER TREATMENT!
A“REMARKABLE” new treatment is being hailed as a potential cure for breast cancer after it “shattered expectations” in worldwide trials!
Already FDA approved for limited use in adults, the AstraZeneca drug, Enhertu, is a game changer in the fight against HER2-positive metastatic breast cancer, according to experts.
“We’re opening up the possibility for some women that a cure could be possible in advanced disease,” said Dave Fredrickson, AstraZeneca’s head of oncology.
In a trial involving patients in the U.S., Asia, Oceania and South America, the drug slashed the risk of disease progression or death by a massive 72 percent compared to a similar medication.
Despite initial treatment with a monoclonal antibody and chemotherapy, patients with HER2-positive metastatic breast cancer often experience disease progression within a year. But Enhertu showed superior life-saving benefits in the head-to-head trial with another antibody-drug conjugate, Kadcyla. According to the data reported at the European Society for Medical Oncology 2021 meeting, progressionfree survival was more than tripled with Enhertu. The median time to progression or death was 25.1 months for Enhertu compared to 7.2 months for Kadcyla.
Enhertu also shrunk tumors in 80 percent of patients compared to one-third of Kadcyla’s study group. The drug is approved by the FDA to treat patients with HER2-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body and who have received two or more prior anti-HER2 breast cancer treatments. Enhertu could become “the new standard of care” for those who have previously been treated for the disease, said doctors.
“The results are groundbreaking and unprecedented,” added Susan Galbraith, executive vice president of oncology research and development at AstraZeneca. “Enhertu has the potential to transform more patient lives in earlier treatment settings.”